CFO exercised or converted 13K EW derivative securities | OQRO Insider tradesWhy it stands out
Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
All the details
Dates, kept separate
- Transaction date
- Apr 9, 2026
- Reporting period
- Not applicable
- Filed with the SEC
- Apr 9, 2026
CFOOption exercise
Context
- Classification
option exercise
Code M — exercise or conversion of a derivative security
- Planned / mechanical clue
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
Source receipt
- Record ID
- 0001225208-26-004476
Added to OQROOct 2, 2026, 12:27 PM UTC Data qualityVerified: identifiers matched exactly IssuerEdwards Lifesciences Corp Reporting personScott B. Ullem Officer titleCVP, Chief Financial Officer TableNon-derivative (Table I) Transaction dateApr 9, 2026 Acquired / disposedAcquired (A) Footnotes from the filing
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 29, 2025.
Around the same time
Routine share withholding; mechanical by default.
Routine share withholding; mechanical by default.
Compensation award — excluded from discretionary-purchase analysis.
